One large cohort study which recruited 1110 Chinese CRC patients revealed that mutant KRAS and BRAF were associated with right-sited tumors [40] and it correlated with the poor response to epidermal growth factor receptor (EGFR) inhibition with cetuximab [41]. Here, KRAS is linked to colorectal carcinoma.